SPRY Stock Overview
A biopharmaceutical company, develops treatments for severe allergic reactions.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
ARS Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$9.03 |
52 Week High | US$11.27 |
52 Week Low | US$2.55 |
Beta | 0 |
1 Month Change | 6.61% |
3 Month Change | 25.94% |
1 Year Change | 5.37% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 49.01% |
Recent News & Updates
Shareholder Returns
SPRY | US Biotechs | US Market | |
---|---|---|---|
7D | 3.3% | 3.2% | 1.7% |
1Y | 5.4% | 6.2% | 26.3% |
Return vs Industry: SPRY matched the US Biotechs industry which returned 6% over the past year.
Return vs Market: SPRY underperformed the US Market which returned 26.3% over the past year.
Price Volatility
SPRY volatility | |
---|---|
SPRY Average Weekly Movement | 8.3% |
Biotechs Industry Average Movement | 11.1% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 16.0% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: SPRY has not had significant price volatility in the past 3 months.
Volatility Over Time: SPRY's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 25 | Rich Lowenthal | ars-pharma.com |
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
ARS Pharmaceuticals, Inc. Fundamentals Summary
SPRY fundamental statistics | |
---|---|
Market cap | US$874.96m |
Earnings (TTM) | -US$49.70m |
Revenue (TTM) | US$10.00k |
Over9,999x
P/S Ratio-17.6x
P/E RatioIs SPRY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SPRY income statement (TTM) | |
---|---|
Revenue | US$10.00k |
Cost of Revenue | US$18.75m |
Gross Profit | -US$18.74m |
Other Expenses | US$30.96m |
Earnings | -US$49.70m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.51 |
Gross Margin | -187,380.00% |
Net Profit Margin | -496,960.00% |
Debt/Equity Ratio | 0% |
How did SPRY perform over the long term?
See historical performance and comparison